Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.62 |
| ▸ | GAK | O14976 | 1/20 | 0.62 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.51 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118440 | 0.88 | EGFR (0.63) | EGFRERBB2GAKMAP3K8MAPK13 | |
| SCHEMBL6640289 | 0.83 | EGFR (0.66) | EGFRERBB2GAK | |
| SCHEMBL5111293 | 0.83 | MAP3K8 (0.79) | EGFRERBB2MAP3K8MAPK13EIF2AK2 | |
| SCHEMBL6381476 | 0.82 | EGFR (0.75) | EGFRERBB2GAKMAP2K1 | |
| SCHEMBL6644272 | 0.82 | EGFR (0.69) | EGFRERBB2GAK | |
| SCHEMBL2994863 | 0.81 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL6380823 | 0.80 | EGFR (0.75) | EGFRERBB2GAKMAP2K1 | |
| SCHEMBL7563757 | 0.79 | EGFR (0.71) | EGFRERBB2GAKMAP3K8MAP2K1 | |
| SCHEMBL28774455 | 0.78 | MAP3K8 (0.82) | EGFRERBB2MAP3K8MAPK13EIF2AK2 | |
| SCHEMBL6381853 | 0.77 | EGFR (1.00) | EGFRERBB2GAKMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | claimed |
| EP-1881981-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-01-30 | — | — | EP | claimed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| WO-2006124944-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | claimed |
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432279-B2 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1881981-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | Wyeth (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| WO-2006124944-A1 | 4, 6-DIAMINO-[1,7] NAPHTHYRIDINE-3-CARBONITRILE INHIBITORS OF TPL2 KINASE AND METHODS OF MAKING AND USING THE SAME | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1171440-B1 | SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | WYETH CORP (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6548496-B2 | Anticancer agents | AMERICAN CYANAMID COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | AMERICAN CYANAMID COMPANY | 2002-11-07 | — | — | US | disclosed |
| US-6355636-B1 | ENZYME INHIBITORS | AMERICAN CYANAMID COMPANY | 2002-03-12 | — | — | US | disclosed |
| EP-1171440-A1 | SUBSTITUTED-3-CYANO-[1.7],[1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | American Cyanamid Company (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000066583-A1 | SUBSTITUTED 3-CYANO-[1.7], [1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | AMERICAN CYANAMID COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276498-A1 | 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CNKSR1, DTYMK | EGFR 2871/4885ERBB2 1101/4885GAK 345/4885 |
| US-20020165229-A1 | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases | ABL1, ROS1, ALK | EGFR 14/4885ERBB2 4/4885GAK 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.